Search research articles
Contact Us
Filters
Showing results (451-460 of 505) with videos related to
Page
of 51
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Naval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.
Science Signaling
|
February 18, 2016
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
Jo Ishizawa, Kensuke Kojima, Dhruv Chachad, et al.
American Journal of Hematology
|
May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Blood
|
March 14, 2007
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia
Chiara Gregorj, Maria R Ricciardi, Maria T Petrucci, et al.
Blood
|
June 20, 2023
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells
Bing Z Carter, Po Yee Mak, Muharrem Muftuoglu, et al.
Scientific Reports
|
February 22, 2017
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
Michele Milella, Italia Falcone, Fabiana Conciatori, et al.
Haematologica
|
May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
Lina Han, Qi Zhang, Monique Dail, et al.
Journal of Hematology & Oncology
|
November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias
Jayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
British Journal of Haematology
|
August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
Kelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.
Page
of 51
Search research articles
Search
Showing results (451-460 of 505) with videos related to
Sort By:
Page
of 51
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Naval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.
Science Signaling
|
February 18, 2016
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
Jo Ishizawa, Kensuke Kojima, Dhruv Chachad, et al.
American Journal of Hematology
|
May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Blood
|
March 14, 2007
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia
Chiara Gregorj, Maria R Ricciardi, Maria T Petrucci, et al.
Blood
|
June 20, 2023
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells
Bing Z Carter, Po Yee Mak, Muharrem Muftuoglu, et al.
Scientific Reports
|
February 22, 2017
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
Michele Milella, Italia Falcone, Fabiana Conciatori, et al.
Haematologica
|
May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
Lina Han, Qi Zhang, Monique Dail, et al.
Journal of Hematology & Oncology
|
November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias
Jayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
British Journal of Haematology
|
August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
Kelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.
Page
of 51